29 related articles for article (PubMed ID: 38599127)
1. Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.
Johnson SD; Levingston C; Young MR
Anticancer Res; 2016 Jul; 36(7):3261-70. PubMed ID: 27354582
[TBL] [Abstract][Full Text] [Related]
2. Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers.
Rykkelid AM; Sinha PM; Folefac CA; Horsman MR; Sørensen BS; Søland TM; Schreurs OJF; Malinen E; Edin NFJ
Sci Rep; 2024 May; 14(1):11569. PubMed ID: 38773258
[TBL] [Abstract][Full Text] [Related]
3. Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols.
Barboy O; Bercovich A; Li H; Eyal-Lubling Y; Yalin A; Shapir Itai Y; Abadie K; Zada M; David E; Shlomi-Loubaton S; Katzenelenbogen Y; Jaitin DA; Gur C; Yofe I; Feferman T; Cohen M; Dahan R; Newell EW; Lifshitz A; Tanay A; Amit I
Nat Cancer; 2024 May; 5(5):742-759. PubMed ID: 38429414
[TBL] [Abstract][Full Text] [Related]
4. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.
Yun J; Saddawi-Konefka R; Goldenson B; Al-Msari R; Bernareggi D; Thangaraj JL; Tang S; Patel SH; Luna SM; Gutkind JS; Kaufman D
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702144
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Proteomic Changes in Tumor and Immune Organs Reveal Systemic Immune Response to Tumor Development.
Li Z; Liu S; Gao Z; Ji L; Jiao J; Zheng N; Li X; Wang G; Qin J; Wang Y
Mol Cell Proteomics; 2024 May; 23(5):100756. PubMed ID: 38554776
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
7. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
[TBL] [Abstract][Full Text] [Related]
8. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
Kenison JE; Wang Z; Yang K; Snyder M; Quintana FJ; Sherr DH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941684
[TBL] [Abstract][Full Text] [Related]
9. CD4
Piersiala K; Farrajota Neves da Silva P; Hjalmarsson E; Kolev A; Kågedal Å; Starkhammar M; Elliot A; Marklund L; Margolin G; Munck-Wikland E; Kumlien Georén S; Cardell LO
Cancer Sci; 2021 Mar; 112(3):1048-1059. PubMed ID: 33462898
[TBL] [Abstract][Full Text] [Related]
10. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
[TBL] [Abstract][Full Text] [Related]
11. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
12. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
13. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
